These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
478 related articles for article (PubMed ID: 26752547)
1. Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma. Taniguchi K; Takata K; Chuang SS; Miyata-Takata T; Sato Y; Satou A; Hashimoto Y; Tamura M; Nagakita K; Ohnishi N; Noujima-Harada M; Tabata T; Kikuti YY; Maeda Y; Nakamura N; Tanimoto M; Yoshino T Am J Surg Pathol; 2016 Mar; 40(3):324-34. PubMed ID: 26752547 [TBL] [Abstract][Full Text] [Related]
2. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma. Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469 [TBL] [Abstract][Full Text] [Related]
3. CD79B and MYD88 mutations in diffuse large B-cell lymphoma. Kim Y; Ju H; Kim DH; Yoo HY; Kim SJ; Kim WS; Ko YH Hum Pathol; 2014 Mar; 45(3):556-64. PubMed ID: 24444466 [TBL] [Abstract][Full Text] [Related]
4. Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations. Cao XX; Li J; Cai H; Zhang W; Duan MH; Zhou DB Ann Hematol; 2017 Nov; 96(11):1867-1871. PubMed ID: 28803429 [TBL] [Abstract][Full Text] [Related]
5. MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma. Aggarwal V; Das A; Bal A; Srinivasan R; Das R; Prakash G; Malhotra P; Varma S Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):311-318. PubMed ID: 29734251 [TBL] [Abstract][Full Text] [Related]
6. Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma. Chen Z; Zou Y; Liu W; Guan P; Tao Q; Xiang C; Zhang W; Ye Y; Yan J; Zhao S Am J Surg Pathol; 2020 Apr; 44(4):444-455. PubMed ID: 31609782 [TBL] [Abstract][Full Text] [Related]
7. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases. Dubois S; Viailly PJ; Bohers E; Bertrand P; Ruminy P; Marchand V; Maingonnat C; Mareschal S; Picquenot JM; Penther D; Jais JP; Tesson B; Peyrouze P; Figeac M; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Fabiani B; Delarue R; Peyrade F; André M; Ketterer N; Leroy K; Salles G; Molina TJ; Tilly H; Jardin F Clin Cancer Res; 2017 May; 23(9):2232-2244. PubMed ID: 27923841 [No Abstract] [Full Text] [Related]
8. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma. Choi JW; Kim Y; Lee JH; Kim YS Hum Pathol; 2013 Jul; 44(7):1375-81. PubMed ID: 23380077 [TBL] [Abstract][Full Text] [Related]
9. Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma. Zheng M; Perry AM; Bierman P; Loberiza F; Nasr MR; Szwajcer D; Del Bigio MR; Smith LM; Zhang W; Greiner TC Neuropathology; 2017 Dec; 37(6):509-516. PubMed ID: 28856744 [TBL] [Abstract][Full Text] [Related]
10. Clinicopathological features of 49 primary gastrointestinal diffuse large B-cell lymphoma cases; comparison with location, cell-of-origin, and frequency of MYD88 L265P. Nagakita K; Takata K; Taniguchi K; Miyata-Takata T; Sato Y; Tari A; Ohnishi N; Noujima-Harada M; Omote S; Nakamura N; Iwamuro M; Maeda Y; Okada H; Tanimoto M; Yoshino T Pathol Int; 2016 Aug; 66(8):444-52. PubMed ID: 27439595 [TBL] [Abstract][Full Text] [Related]
11. MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome. Rovira J; Karube K; Valera A; Colomer D; Enjuanes A; Colomo L; Martínez-Trillos A; Giné E; Dlouhy I; Magnano L; Delgado J; Martínez A; Villamor N; Campo E; López-Guillermo A Clin Cancer Res; 2016 Jun; 22(11):2755-64. PubMed ID: 26792260 [TBL] [Abstract][Full Text] [Related]
12. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Nakamura T; Tateishi K; Niwa T; Matsushita Y; Tamura K; Kinoshita M; Tanaka K; Fukushima S; Takami H; Arita H; Kubo A; Shuto T; Ohno M; Miyakita Y; Kocialkowski S; Sasayama T; Hashimoto N; Maehara T; Shibui S; Ushijima T; Kawahara N; Narita Y; Ichimura K Neuropathol Appl Neurobiol; 2016 Apr; 42(3):279-90. PubMed ID: 26111727 [TBL] [Abstract][Full Text] [Related]
13. High prevalence of the MYD88 mutation in testicular lymphoma: Immunohistochemical and genetic analyses. Oishi N; Kondo T; Nakazawa T; Mochizuki K; Tanioka F; Oyama T; Yamamoto T; Iizuka J; Tanabe K; Shibata N; Kirito K; Katoh R Pathol Int; 2015 Oct; 65(10):528-35. PubMed ID: 26388135 [TBL] [Abstract][Full Text] [Related]
14. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma. Bohers E; Mareschal S; Bouzelfen A; Marchand V; Ruminy P; Maingonnat C; Ménard AL; Etancelin P; Bertrand P; Dubois S; Alcantara M; Bastard C; Tilly H; Jardin F Genes Chromosomes Cancer; 2014 Feb; 53(2):144-53. PubMed ID: 24327543 [TBL] [Abstract][Full Text] [Related]
15. Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations. Yamada S; Ishida Y; Matsuno A; Yamazaki K Leuk Lymphoma; 2015 Jul; 56(7):2141-5. PubMed ID: 25347427 [TBL] [Abstract][Full Text] [Related]
16. The Prevalence of MYD88 L265P and TNFAIP3 Mutations and Their Correlations with Clinico-Hematological Profile in Egyptian Patients with Diffuse Large B Cell Lymphoma. Elbaz O; Shaat RM; Abd El Ghaffar HA; Shamaa S; Abdel-Masseih HM; Anber N; Mortada MI Asian Pac J Cancer Prev; 2023 Jul; 24(7):2485-2491. PubMed ID: 37505783 [TBL] [Abstract][Full Text] [Related]
17. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease. Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994 [TBL] [Abstract][Full Text] [Related]
18. B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice. Knittel G; Liedgens P; Korovkina D; Seeger JM; Al-Baldawi Y; Al-Maarri M; Fritz C; Vlantis K; Bezhanova S; Scheel AH; Wolz OO; Reimann M; Möller P; López C; Schlesner M; Lohneis P; Weber AN; Trümper L; ; Staudt LM; Ortmann M; Pasparakis M; Siebert R; Schmitt CA; Klatt AR; Wunderlich FT; Schäfer SC; Persigehl T; Montesinos-Rongen M; Odenthal M; Büttner R; Frenzel LP; Kashkar H; Reinhardt HC Blood; 2016 Jun; 127(22):2732-41. PubMed ID: 27048211 [TBL] [Abstract][Full Text] [Related]
19. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia. Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631 [TBL] [Abstract][Full Text] [Related]
20. Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma. Gebauer N; Hardel TT; Gebauer J; Bernard V; Merz H; Feller AC; Rades D; Biersack H; Lehnert H; Thorns C Anticancer Res; 2014 Oct; 34(10):5503-7. PubMed ID: 25275047 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]